ID26964A - Komposisi dan metode untuk pengaturan pengaktifan limfosit - Google Patents

Komposisi dan metode untuk pengaturan pengaktifan limfosit

Info

Publication number
ID26964A
ID26964A IDW20001845A ID20001845A ID26964A ID 26964 A ID26964 A ID 26964A ID W20001845 A IDW20001845 A ID W20001845A ID 20001845 A ID20001845 A ID 20001845A ID 26964 A ID26964 A ID 26964A
Authority
ID
Indonesia
Prior art keywords
limfosit
activities
composition
setting
methods
Prior art date
Application number
IDW20001845A
Other languages
English (en)
Indonesian (id)
Inventor
Jeffrey A Ledbetter
Martha Hayden Ledbetter
William A Brady
Laura S Grosmaire
Che-Leung Law
Raj Dua
Original Assignee
Xcyte Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcyte Therapies Inc filed Critical Xcyte Therapies Inc
Publication of ID26964A publication Critical patent/ID26964A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20001845A 1998-02-19 1999-02-18 Komposisi dan metode untuk pengaturan pengaktifan limfosit ID26964A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7527498P 1998-02-19 1998-02-19
US10868398P 1998-11-16 1998-11-16

Publications (1)

Publication Number Publication Date
ID26964A true ID26964A (id) 2001-02-22

Family

ID=26756645

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001845A ID26964A (id) 1998-02-19 1999-02-18 Komposisi dan metode untuk pengaturan pengaktifan limfosit

Country Status (14)

Country Link
US (3) US20020155604A1 (fr)
EP (1) EP1469883A2 (fr)
JP (1) JP2003525016A (fr)
KR (1) KR20010034512A (fr)
CN (1) CN1316910A (fr)
AU (1) AU3295299A (fr)
BR (1) BR9907950A (fr)
CA (1) CA2321199A1 (fr)
HK (1) HK1041210A1 (fr)
ID (1) ID26964A (fr)
IL (1) IL137963A0 (fr)
NO (1) NO20004095L (fr)
NZ (1) NZ506453A (fr)
WO (1) WO1999042077A2 (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637160A3 (fr) 1999-05-07 2006-05-03 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes B
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
ATE513854T1 (de) * 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US8163289B2 (en) 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2002072608A2 (fr) 2001-03-09 2002-09-19 University Of Chicago Proteines hybrides d'immunoglobulines polymeriques ciblant des recepteurs fc$g(g) a faible affinite
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7371849B2 (en) * 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
MXPA04003291A (es) * 2001-10-12 2004-07-23 Schering Corp Uso de anticuerpos biespecificos para ragular respuestas inmunes.
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US20090217404A1 (en) * 2002-09-27 2009-08-27 Lowe Scott W Cell-based RNA interference and related methods and compositions
US20090186839A1 (en) * 2003-02-17 2009-07-23 Cold Spring Harbor Laboratory Model for studying the role of genes in chemoresistance
CA2516022C (fr) * 2003-02-17 2012-05-29 Cold Spring Harbor Laboratory Modele d'etude du role de genes dans la resistance de tumeur a la chimiotherapie
ATE481476T1 (de) * 2003-05-08 2010-10-15 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t- zellen
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
JP4818917B2 (ja) * 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
WO2005030251A1 (fr) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions et methodes pour accelerer une guerison hematologique
WO2005049085A1 (fr) * 2003-11-18 2005-06-02 Valeocyte Therapies Llc Utilisation de complexes solubles pour faciliter l'activation cellulaire
WO2005075515A2 (fr) * 2004-02-06 2005-08-18 Unilever N.V. Immunoglobulines et leur procede de modification
US20070264277A1 (en) 2004-07-22 2007-11-15 Dirk Behrens Compositions and Methods of Use for Mgd-Csf in Disease Treatment
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
CN105535967B (zh) * 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
AU2006244445B2 (en) * 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CA2960105A1 (fr) 2005-05-20 2006-11-23 Ablynx Nv Nanobodies (nanocorps) perfectionnes pour traiter des troubles medies par une agregation
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2007053184A2 (fr) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methode de production de micro-arns
EP1904101A4 (fr) * 2005-06-08 2011-06-15 Univ Duke Therapie a anticorps diriges contre cd19 a des fins de transplantation
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
EP2066349B1 (fr) 2006-09-08 2012-03-28 MedImmune, LLC Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2102244A2 (fr) 2006-12-19 2009-09-23 Ablynx N.V. Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
EP2260058A2 (fr) 2008-04-07 2010-12-15 Ablynx N.V. Séquences d acides aminés dirigées contre les voies notch et leurs utilisations
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2313436B1 (fr) 2008-07-22 2014-11-26 Ablynx N.V. Séquences d acides aminés dirigées contre des récepteurs de désactiveurs multicibles et polypeptides
MX338825B (es) 2008-10-02 2016-05-03 Emergent Product Dev Seattle Proteinas de enlace a objetivos multiples de antagonistas de cd86.
JP5647222B2 (ja) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
DK2438087T3 (en) 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
CA2780753A1 (fr) * 2009-11-14 2011-05-19 Kuang-Yuh Chyu Procedes et systemes d'immunomodulation pour le traitement et/ou la prevention de l'atherosclerose
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (fr) 2009-12-14 2011-06-23 Ablynx N.V. Anticorps à domaine variable unique dirigés contre ox4ql, produits de recombinaison et utilisation thérapeutique
WO2011083140A1 (fr) 2010-01-08 2011-07-14 Ablynx Nv Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098518A2 (fr) 2010-02-11 2011-08-18 Ablynx Nv Administration de domaines variables d'immunoglobuline et de produits de construction de ceux-ci
WO2011117423A1 (fr) 2010-03-26 2011-09-29 Ablynx N.V. Domaines variables uniques de l'immunoglobuline dirigés contre cxcr7
WO2011144749A1 (fr) 2010-05-20 2011-11-24 Ablynx Nv Matériaux biologiques associés à her3
WO2011161263A1 (fr) 2010-06-25 2011-12-29 Ablynx Nv Compositions pharmaceutiques destinées à une administration par voie cutanée
WO2012042026A1 (fr) 2010-09-30 2012-04-05 Ablynx Nv Matières biologiques associées à c-met
EP3578568A3 (fr) 2010-11-08 2020-01-08 Ablynx N.V. Polypeptides se liant aux récepteurs de cxcr2
CA2827170A1 (fr) 2011-02-11 2012-08-16 David M. Hilbert Complexes plurispecifiques monovalents et multivalents et leurs utilisations
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
WO2013036130A1 (fr) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Vhh à neutralisation large dirigés contre le vih-1
EP2747782B1 (fr) 2011-09-23 2018-01-17 Ablynx NV Inhibition prolongée d'une signalisation à médiation par l'interleukine-6
EP2760892A1 (fr) * 2011-09-29 2014-08-06 Apo-T B.V. Molécules de liaison multispécifiques ciblant des cellules aberrantes
CA2850261C (fr) 2011-09-30 2021-04-20 Ablynx Nv Domaines de variable simple d'immunoglobuline c-met
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US20130183307A1 (en) 2012-01-13 2013-07-18 Johan Renes Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (fr) 2012-12-07 2014-06-12 Ablynx N.V. Polypeptides améliorés dirigés contre ige
WO2015000624A1 (fr) * 2014-05-19 2015-01-08 F. Hoffmann-La Roche Ag Procédé pour produire des anticorps au moyen de lymphocytes b ovins et ses utilisations
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AU2015283704A1 (en) 2014-07-01 2016-12-15 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
RU2700650C2 (ru) 2014-10-10 2019-09-18 Аблинкс Н.В. Игаляционное устройство для использования в аэрозольной терапии респираторных заболеваний
JP2017538779A (ja) 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
CN107646039B (zh) 2015-04-02 2022-04-15 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
CN107708720A (zh) 2015-04-06 2018-02-16 苏伯多曼有限责任公司 含有从头结合结构域的多肽及其用途
LT3294768T (lt) 2015-05-13 2019-11-11 Ablynx Nv T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
JP7163028B2 (ja) * 2015-05-13 2022-10-31 アブリンクス エン．ヴェー． Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
CA3003334A1 (fr) * 2015-10-28 2017-05-04 Life Technologies As Multiplication selective de differentes sous-populations de cellules t par la modification de signaux de surface cellulaire et du rapport des signaux
NO2768984T3 (fr) 2015-11-12 2018-06-09
CN108473561B (zh) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 抑制cd40l的多肽
JP2019512544A (ja) * 2016-03-15 2019-05-16 ネックスジェニア インコーポレイテッド 細胞表面分子結合性の刺激応答性重合体組成物および方法
EP4273232A3 (fr) 2016-03-30 2024-01-03 F. Hoffmann-La Roche AG Procédé de culture de lymphocyte b
CA3022697A1 (fr) 2016-05-02 2017-11-09 Ablynx Nv Traitement d'une infection a vrs
WO2018007442A1 (fr) 2016-07-06 2018-01-11 Ablynx N.V. Traitement de maladies associées à l'il-6r
WO2018029182A1 (fr) 2016-08-08 2018-02-15 Ablynx N.V. Anticorps à domaine variable unique d'il-6r pour le traitement de maladies liées à l'il-6r
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3541846A1 (fr) 2016-11-16 2019-09-25 Ablynx NV Polypeptides de recrutement de lymphocytes t capables de se lier à cd123 et tcr alpha/bêta
WO2018099968A1 (fr) 2016-11-29 2018-06-07 Ablynx N.V. Traitement d'une infection par le virus respiratoire syncytial (vrs)
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
WO2018122147A1 (fr) 2017-01-02 2018-07-05 F. Hoffmann-La Roche Ag Procédé de culture de lymphocytes b
WO2018206734A1 (fr) 2017-05-11 2018-11-15 Vib Vzw Glycosylation de domaines variables d'immunoglobuline
CN110621773B (zh) 2017-05-19 2023-06-09 豪夫迈·罗氏有限公司 用于产生胸腺细胞上清液的方法
MX2019014400A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Inmunoglobulinas que se unen a adamts.
AU2018278275A1 (en) 2017-06-02 2019-12-19 Ablynx N.V. MMP13 binding immunoglobulins
CA3065630A1 (fr) 2017-06-02 2018-12-06 Ablynx Nv Immunoglobulines liant l'aggrecane
WO2018220236A1 (fr) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides se liant à adamts5, mmp13 et à l'aggrécane
JP7285267B2 (ja) 2017-11-14 2023-06-01 アーセルクス インコーポレイテッド Ｄドメイン含有ポリペプチドおよびその使用
EP3717632B1 (fr) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG Procédé de culture de lymphocyte b
CA3090321A1 (fr) 2018-02-05 2019-08-08 Stichting Vu Anticorps anti-us28 agonistes inverses
WO2019156566A1 (fr) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Molécules bispécifiques comprenant un tcr gamma-delta et un domaine de liaison de lymphocytes t ou de cellules nk
CN111655296A (zh) 2018-02-26 2020-09-11 埃博灵克斯股份有限公司 编码肽接头的经改良核苷酸序列
WO2019226050A2 (fr) 2018-05-24 2019-11-28 Wageningen Universiteit Nouveaux réactifs anti-infectieux viraux
EP3636657A1 (fr) 2018-10-08 2020-04-15 Ablynx N.V. Procédé de purification d'anticorps sans chromatographie
WO2020080941A1 (fr) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anticorps anti-protéine 5/6 associée au récepteur de lipoprotéines de faible densité
WO2020130838A2 (fr) 2018-12-21 2020-06-25 Qvq Holding B.V. Anticorps pour la prévention ou le traitement de la candidose
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
EP3946434A1 (fr) 2019-04-02 2022-02-09 Immunetune B.V. Compositions immunostimulantes et leur utilisation
WO2020245663A1 (fr) 2019-06-01 2020-12-10 Institut Pasteur Dosage ns1 à base de nanocorps pour le diagnostic spécifique d'une infection aiguë par le virus zika
EP4010079A1 (fr) 2019-08-05 2022-06-15 Stichting VU Identification et élimination de cellules infectées par hcmv
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
US20240092919A1 (en) 2020-12-18 2024-03-21 Ablynx N. V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
WO2022216157A1 (fr) 2021-04-09 2022-10-13 Stichting Radboud Universiteit Enzyme de biotinylation de proximité immédiate
WO2022258606A1 (fr) 2021-06-07 2022-12-15 Gadeta B.V. Chaînes de récepteurs de lymphocytes t delta ou de lymphocytes t gamma ou parties associées induisant une réponse antitumorale ou anti-infectieuse
EP4381094A1 (fr) 2021-08-03 2024-06-12 Wageningen Universiteit Système de détection d'acide nucléique à base d'argonaute
WO2023227594A1 (fr) 2022-05-24 2023-11-30 Gadeta Bv Nouvelles chaînes de récepteurs de cellules t delta et chaînes de récepteurs de cellules t gamma ou parties de celles-ci
WO2023237541A1 (fr) 2022-06-07 2023-12-14 Gadeta B.V. Chaînes de récepteurs de lymphocytes t delta ou de lymphocytes t gamma ou des parties de celles-ci qui médient une réponse anti-tumorale ou anti-infectieuse
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024017915A1 (fr) 2022-07-18 2024-01-25 Ablynx N.V. Composés de liaison à cx3cr1, leurs utilisations et procédés associés
WO2024023271A1 (fr) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r
WO2024096735A1 (fr) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Anticorps anti-cd169 à domaine unique
WO2024101989A1 (fr) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Récepteurs d'antigènes inductibles par activation pour immunothérapie adoptive

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
AP257A (en) * 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
EP0584421A1 (fr) * 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulines dépourvus de chaînes légères

Also Published As

Publication number Publication date
HK1041210A1 (zh) 2002-07-05
EP1469883A2 (fr) 2004-10-27
WO1999042077A2 (fr) 1999-08-26
CA2321199A1 (fr) 1999-08-26
US20040253250A1 (en) 2004-12-16
KR20010034512A (ko) 2001-04-25
IL137963A0 (en) 2001-10-31
AU3295299A (en) 1999-09-06
JP2003525016A (ja) 2003-08-26
BR9907950A (pt) 2001-12-18
US20050261478A1 (en) 2005-11-24
NZ506453A (en) 2003-02-28
WO1999042077A3 (fr) 2004-05-27
NO20004095L (no) 2000-10-18
NO20004095D0 (no) 2000-08-16
US20020155604A1 (en) 2002-10-24
CN1316910A (zh) 2001-10-10

Similar Documents

Publication Publication Date Title
ID26964A (id) Komposisi dan metode untuk pengaturan pengaktifan limfosit
ID22889A (id) Komposisi kopolimer etilena dan penggunaannya
ID29591A (id) Senyawa-senyawa kuinolina dan kuinoksalina
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
ID29013A (id) Ligan-ligan reseptor novel thiroid dan metode ii
ID28728A (id) Komposisi dan proses pengkrepan
ID24196A (id) Komposisi dan penggunaan
ID22957A (id) Senyawa dan penggunaannya
ID18354A (id) Metoda dan susunan untuk komunikasi radio
ATE446389T1 (de) Enzymgemisch
NO20002470D0 (no) Ny materialsammensetning
DE69703048D1 (de) Glaszusammensetzung, verfahren und verwendung
ID19422A (id) Piridina dan bifenil tersubstitusi
DE69939748D1 (de) Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
IS5430A (is) Ný samsetning
ID27680A (id) Komposisi poliester, metoda produksi daripadanya dan film poliester
ID22009A (id) Metoda dan peralatan destilasi
ID26599A (id) Turunan triazola dan imidazola
PT1123441E (pt) Composicoes e metodos para preparar dispersoes e metodos para utilizar as dispersoes
ID29053A (id) Metode untuk menghasilkan 3-alkanoilindola dan 3-alkilindola
ID28752A (id) Metode-metode dan komposisi-komposisi sanitasi
ID16889A (id) Senyawa turunan alkilaminobenzotiazol dan benzoksazol
DE69916503D1 (de) Poliermittelzusammensetzung und anwendungsverfahren
ID24872A (id) Komposisi pengawet berdasarkan senyawa donor formaldehide dan iodopropinil
ID29547A (id) Metoda dan komposisi untuk pencegahan dan pengobatan tuberkulosis